A highly-selective HPGDS inhibitor, TAS-205, was found to reduce necrosis and improve locomotor activity in mdx mice [104]; although no more specific results are available on its regenerative potential, a recent Phase I trial provided early evidence of a modest if any, potential therapeutic activity in DMD population (NCT02246478). This evidence concerns the gene HPGDS and Duchenne muscular dystrophy.